Mylatrip (Frovatriptan Succinate Monohydrate)

Frovatriptan succinate monohydrate, the active ingredient in Mylatrip, is a Triptan presented as an oral tablet for oral use. It is indicated for the acute treatment of migraine attacks in adults. GNH USA supplies Mylatrip as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Frovatriptan belongs to the triptan class and is used for acute migraine management. - Migraine without aura: provides rapid relief of headache pain and associated symptoms. - Migraine with aura: aborts the headache phase after aura has occurred. - Acute migraine attacks: reduces severity and duration when taken at the first sign of an attack.

Frovatriptan may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects: - Chest discomfort or tightness - Tingling or numbness in the fingers or toes - Nausea or abdominal pain - Dizziness or light‑headedness - Fatigue or drowsiness - Dry mouth

Serious or Rare Side Effects: - Coronary vasospasm or myocardial infarction - Serotonin syndrome, especially with serotonergic agents - Severe allergic reaction (anaphylaxis, angioedema) - Persistent hypertension - Severe abdominal pain or gastrointestinal bleeding - Vision changes or visual field defects

Before prescribing frovatriptan, clinicians should evaluate patient‑specific risk factors and contraindications. - Cardiovascular assessment: avoid in patients with uncontrolled coronary artery disease. - Drug contraindications: do not use with ergot derivatives or other triptans. - Dose limitation: do not exceed the recommended maximum number of doses per month. - Hepatic impairment: use with caution in patients with liver dysfunction. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Frovatriptan can interact with several medication classes, requiring careful review.

Major Interactions (Avoid): - MAO inhibitors: risk of severe hypertension and serotonin syndrome. - Other triptans or ergot alkaloids: additive vasoconstrictive effects. - SSRIs, SNRIs, or other serotonergic agents: increased risk of serotonin syndrome.

Moderate Interactions (Monitor Closely): - CYP1A2 inhibitors (e.g., fluvoxamine): may increase frovatriptan plasma levels. - CYP1A2 inducers (e.g., smoking, carbamazepine): may reduce efficacy. - Antihypertensive agents: monitor blood pressure for additive effects.